Home> Companies

Guizhou Liding Medical Network Technology

Updated: 2019-11-14 17:05:28

Website: www.ldxxw.com.cn

Tel: +86-400-632-5588

Address: 7-8F, Big Data Innovation Center, No 818, Kaifa Avenue, Guiyang Economic and Technological Development Zone, Guiyang city, Guizhou province

Guizhou Liding Medical Network Technology is a national high-tech enterprise focusing on telemedicine network technology service, medical system development, and medical device research and development, production and operation.

The company was established in February 2009 and was transformed into a joint-stock company on March 18, 2016. It was successfully listed on China's National Equities Exchange and Quotations, also known as the "new third board," in August 2016 with the stock symbol of 839093.

So far, the company's software products have earned 32 patents and independent intellectual property rights.

Its newborn screening blood sample collection special card and newborn disease screening intelligent work platform V1.01 is currently used in more than 4,000 medical institutions in 31 provinces and cities nationwide, achieving significant social and economic benefits.

The cervical cancer inspection management platform V1.01 is the only operational network platform the National Maternal and Child Health Center has designated to launch a pilot program for cervical cancer screening for rural women in eight provinces across the country.

In Nov 2017, the company was made a massive health medicine industry and big data development demonstration base in Guizhou province.

The company topped the "China Digital Valley" big data application TOP100 selection at the 2018 Big Data Expo.

In Sept 2018, its "Newborn Disease Screening Intelligent Platform" project was included in the "2018 Big Data Industry Development Pilot Demonstration Projects" (a cross-industry big data fusion application) of the Ministry of Industry and Information Technology.


Guiyang China The People's Government of Guiyang Municipality. All Rights Reserved.
Presented by China Daily.